Drug or treatment

Trastuzumab clinical trials

• 161Clinical trials
• 1New in 30 days
• 52Countries

Newest trials

All recruiting trials (newest 150 of 161)

• Neoadjuvant trastuzumab, durvalumab, and FLOT for HER2-positive gastric or GEJ cancer

  This study tests a pre-surgery treatment combining trastuzumab, durvalumab, and FLOT for patients with HER2-positive locally advanced gastric or gastroesophageal junction cancer to see how many achieve complete tumor disappearance.

  Recruiting Phase 2 Samsung Medical Center · Seoul, Gang-Nam · NCT07911280

• Neoadjuvant Pyrotinib-to-pertuzumab for HER2-positive early breast cancer

  This trial tests whether a two-step neoadjuvant plan with Pyrotinib plus Trastuzumab and Docetaxel followed by Pertuzumab plus Trastuzumab and Docetaxel works better than four cycles of Pertuzumab plus Trastuzumab and Docetaxel in women with HER2-positive early- to locally advanced breast cancer.

  Recruiting Phase 3 Shanghai Jiao Tong University School of Medicine · Shanghai · NCT07797218

• Trastuzumab Rezetecan and Gemcitabine before surgery for HER2-positive UTUC

  This study tests whether giving trastuzumab deruxtecan with gemcitabine before and around surgery can improve outcomes for people with HER2-positive upper tract urothelial cancer.

  Recruiting at 10 sites Phase 2 Tongji Hospital · Huanggang, Hubei and 9 other locations · NCT07741448

• Foslorapitant with Palonosetron to Help Prevent Nausea and Vomiting from Trastuzumab Rezetecan

  A single-arm study tests whether giving foslorapitant plus palonosetron can prevent chemotherapy-induced nausea and vomiting in adults receiving Trastuzumab Rezetecan.

  Recruiting Phase 2 Tianjin Medical University Cancer Institute and Hospital · Tianjin · NCT07726433

• Auricular point stimulation with dexamethasone versus standard antiemetics for nausea from trastuzumab deruxtecan

  This trial tests whether adding ear acupuncture-style stimulation to dexamethasone can prevent and reduce nausea and vomiting caused by trastuzumab deruxtecan in breast cancer patients, compared with the usual antiemetic regimen.

  Recruiting Phase 3 Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou · NCT07716189

• Entinostat with Pyrotinib and Endocrine Therapy in HER2-positive, HR-positive Advanced Breast Cancer after Trastuzumab Failure

  This study tests whether adding entinostat to pyrotinib and hormone therapy is safe and helps patients with advanced HR+/HER2+ breast cancer who progressed after trastuzumab.

  Recruiting Phase 1/2 Tianjin Medical University Cancer Institute and Hospital · Tianjin, Tianjin Municipality · NCT07708194

• Trastuzumab Rezetecan with Adebrelimab and Lenvatinib for advanced HER2-positive/low-expression biliary tract cancer

  This study tests a triple therapy to see if it helps people with advanced biliary tract cancer that is HER2-positive or has low HER2 expression after at least one prior treatment.

  Recruiting Phase 2 Peking Union Medical College Hospital · Beijing, Beijing Municipality · NCT07704177

• Olaparib with Trastuzumab and Pertuzumab before surgery for older women with HER2-positive breast cancer

  This trial tests whether adding olaparib to standard HER2-targeted therapy can help older women with newly diagnosed, operable HER2-positive breast cancer before surgery.

  Recruiting Phase 4 Zhejiang Cancer Hospital · Hangzhou, Zhejiang · NCT07695259

• Dendritic Cell Vaccine with HER2-targeted Therapy or Nivolumab for Breast Cancer with Leptomeningeal Metastasis

  This trial tests a dendritic cell vaccine added to trastuzumab for Her2-positive disease or to nivolumab for Her2-negative disease to see if it can be given safely to people with breast cancer that has spread to the leptomeninges.

  Recruiting Phase 2 H. Lee Moffitt Cancer Center and Research Institute · Tampa, Florida · NCT07694986

• GQ1005 versus T-DM1 in HER2-positive unresectable or metastatic breast cancer

  This trial tests whether GQ1005 works as well as T-DM1 for adults with HER2-positive unresectable or metastatic breast cancer who have already had trastuzumab and taxane.

  Recruiting at 70 sites Phase 3 GeneQuantum Healthcare (Suzhou) Co., Ltd. · Bengbu, Anhui and 69 other locations · NCT07673029

• First-line treatment with Trastuzumab Rezetecan, Adebrelimab, and Lenvatinib for advanced HER2-positive or HER2-low biliary tract cancer

  This phase II trial tests whether a combination of Trastuzumab Rezetecan, Adebrelimab, and Lenvatinib can help people with advanced HER2-positive or HER2-low biliary tract cancer respond to treatment as a first line therapy.

  Recruiting Phase 2 Peking Union Medical College Hospital · Beijing · NCT07670273

• Brain metastases from breast cancer: see how trastuzumab deruxtecan in CSF relates to effect

  This study tests whether levels of trastuzumab deruxtecan in cerebrospinal fluid relate to how well it works for adults with breast cancer that has spread to the brain.

  Recruiting Fudan University · Shanghai, Shanghai Municipality · NCT07653893

• Trastuzumab Rezetecan Neoadjuvant Therapy for HER2-Positive Breast Cancer

  This trial tests whether adding trastuzumab rezetecan after an initial THP treatment helps patients with HER2-positive breast cancer decide if they should switch therapies based on response.

  Recruiting Phase 2 The First Affiliated Hospital of Soochow University · Suzhou, Jiangsu · NCT07647263

• Trastuzumab Deruxtecan plus ivonescimab for HR+ HER2-low advanced breast cancer

  This study tests whether combining Trastuzumab Deruxtecan with ivonescimab can help people with HR-positive, HER2-low metastatic breast cancer after prior CDK4/6 inhibitor therapy.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT07647016

• Pyrotinib plus trastuzumab and chemotherapy for HER2-positive early breast cancer

  This study tests a treatment combination of Pyrotinib, Trastuzumab and chemo given before surgery to see if it can improve responses in HER2-positive breast cancer patients who have not yet been treated.

  Recruiting Phase 2 Hebei Medical University Fourth Hospital · Shijiazhuang, Hebei · NCT07635342

• Combo therapy with selumetinib and trastuzumab deruxtecan for advanced pancreatic cancer

  This phase 1/2 trial tests whether the combination of selumetinib and DS-8201a (trastuzumab deruxtecan) is safe and whether it can help people with unresectable or metastatic pancreatic ductal adenocarcinoma.

  Recruiting Phase 1/2 National Cancer Institute (NCI) · Pittsburgh, Pennsylvania · NCT07619521

• Pyrotinib and Trastuzumab with Dalpiciclib vs with Docetaxel in advanced HER2-positive breast cancer

  This study tests whether an oral regimen of pyrotinib + subcutaneous trastuzumab + dalpiciclib works as well as the standard IV regimen with docetaxel in people with advanced HER2-positive breast cancer who have limited prior treatment.

  Recruiting Phase 3 Fudan University · Shanghai, Shanghai Municipality · NCT07615751

• Tucatinib with trastuzumab and capecitabine for HER2‑positive metastatic breast cancer in routine care

  This project will see if tucatinib combined with trastuzumab and capecitabine works and is safe for people with HER2‑positive metastatic breast cancer who have had at least two prior anti‑HER2 treatments.

  Recruiting at 13 sites Fondazione Oncotech · Avellino, AV and 29 other locations · NCT07583485

• Paclitaxel micelles with HER2-targeted therapy vs standard taxane-based therapy as first-line treatment for advanced HER2-positive breast cancer

  This study tests whether paclitaxel polymer micelles plus trastuzumab, pertuzumab, and ad Adelumab can better treat advanced HER2-positive breast cancer compared with the usual taxane-based therapy plus trastuzumab and pertuzumab.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT07581795

• Megestrol Acetate to Help Fatigue in T-DXd-Treated Breast Cancer

  This study tests whether adding Megestrol Acetate at the start of Trastuzumab Deruxtecan therapy can reduce fatigue and improve quality of life for adults with advanced HER2-positive breast cancer.

  Recruiting Phase 3 Sun Yat-sen University · Guangzhou, Guangdong and 1 other locations · NCT07543536

• Ear acupressure plus dexamethasone to prevent nausea and vomiting from trastuzumab deruxtecan

  This trial will try ear acupressure combined with a standard dose of dexamethasone to prevent or reduce nausea and vomiting in breast cancer patients receiving trastuzumab deruxtecan.

  Recruiting Phase 2 Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou · NCT07537673

• BL-M07D1 plus pertuzumab vs standard therapy in first-line HER2-positive breast cancer

  A Phase 3 trial tests whether adding BL-M07D1 to pertuzumab is as good as or better than docetaxel plus trastuzumab and pertuzumab in patients with newly diagnosed, unresectable or metastatic HER2-positive breast cancer.

  Recruiting at 2 sites Phase 3 Sichuan Baili Pharmaceutical Co., Ltd. · Guangzhou, Guangdong and 1 other locations · NCT07518173

• Trastuzumab plus serplulimab with chemotherapy for HER2-positive advanced biliary tract or urothelial cancer after prior therapy

  This study will test whether adding trastuzumab and serplulimab to chemotherapy helps people with HER2-positive unresectable or metastatic biliary tract cancer or urothelial carcinoma who have not responded to standard treatment.

  Recruiting Phase 2 China Medical University, China · Shenyang, Liaoning · NCT07506057

• Trastuzumab Rezetecan versus Trastuzumab Deruxtecan for unresectable HER2‑low, HR‑positive breast cancer

  This Phase 2 trial tests different doses of Trastuzumab Rezetecan compared with Trastuzumab Deruxtecan in women with HR-positive, HER2-low unresectable locally recurrent or metastatic breast cancer to see which dose is safer and more effective.

  Recruiting Phase 2 Jiangsu HengRui Medicine Co., Ltd. · Beijing, Beijing Municipality · NCT07497386

• KN026 plus HB1801 with chemotherapy as adjuvant treatment after surgery for resectable HER2-positive breast cancer

  This study will test whether giving KN026 and HB1801 with chemotherapy after surgery helps people with resectable HER2-positive breast cancer more than the usual trastuzumab plus pertuzumab with chemotherapy.

  Recruiting Phase 3 Shanghai JMT-Bio Inc. · Shanghai, Shanghai Municipality · NCT07441460

• Whole-body HER2 PET/CT to see how 89Zr-trastuzumab accumulates in HER2-positive or HER2-mutated advanced NSCLC

  This study tests whether 89Zr-trastuzumab PET/CT can show how much tracer builds up in tumors of adults with HER2-positive or HER2-mutated advanced NSCLC.

  Recruiting Phase 1 The Netherlands Cancer Institute · Amsterdam, North Holland · NCT07436858

• Heart health education with VR for breast cancer patients on certain therapies

  This trial tests a virtual reality program to help breast cancer survivors learn about heart health and healthy behaviors while they receive treatments like anthracyclines or trastuzumab.

  Recruiting at 3 sites Virginia Commonwealth University · Richmond, Virginia and 2 other locations · NCT07426913

• RO7771950 versus tucatinib with trastuzumab and capecitabine for HER2-positive locally advanced or metastatic breast cancer

  This test will see if RO7771950 combined with trastuzumab and capecitabine works better than tucatinib combined with the same drugs for people with HER2-positive locally advanced or metastatic breast cancer.

  Recruiting at 219 sites Phase 2/3 Hoffmann-La Roche · Huntsville, Alabama and 218 other locations · NCT07413939

• First-line trastuzumab-deruxtecan with capecitabine and bevacizumab for HER2-positive metastatic colorectal cancer

  This trial tests whether giving trastuzumab-deruxtecan together with capecitabine and bevacizumab as first treatment helps people with HER2-positive metastatic or unresectable colorectal cancer shrink tumors and respond better.

  Recruiting at 28 sites Phase 2 Gruppo Oncologico del Nord-Ovest · Lyon and 27 other locations · NCT07407465

• Pre-surgery trastuzumab deruxtecan (SHR-A1811) plus pertuzumab for HER2-positive breast cancer

  This trial tests giving trastuzumab deruxtecan (SHR-A1811) with pertuzumab before surgery to see if it helps women with stage II–III HER2-positive breast cancer achieve a complete response.

  Recruiting Phase 2 Shanghai Jiao Tong University School of Medicine · Shanghai, Shanghai Municipality · NCT07393425

• Neoadjuvant trastuzumab rezetecan plus toripalimab for HR‑positive, HER2‑low breast cancer

  This trial will test whether giving trastuzumab rezetecan with toripalimab before surgery helps people with HR‑positive/HER2‑low breast cancer shrink tumors and achieve complete responses.

  Recruiting at 5 sites Phase 2 First Affiliated Hospital of Zhejiang University · Harbin and 4 other locations · NCT07383818

• IBI354 with or without pertuzumab versus taxane plus trastuzumab and pertuzumab for HER2-positive metastatic breast cancer

  This trial tests whether IBI354, with or without pertuzumab, works better than standard taxane plus trastuzumab and pertuzumab as first-line treatment for adults with HER2-positive unresectable locally advanced or metastatic breast cancer.

  Recruiting Phase 3 Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. · Beijing, Beijing Municipality · NCT07377643

• Trastuzumab-rezetecan for HER2-positive and HER2-low breast cancer

  This project will test Trastuzumab-rezetecan in adults with HER2-positive or HER2-low breast cancer who are receiving it as part of routine care to see if it works and is safe.

  Recruiting Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou, Guangdong · NCT07358182

• Intensified HER2-targeted treatment for people with a suboptimal response to initial dual HER2 therapy and chemotherapy

  This trial will try stronger targeted drug combinations for people with HER2-positive early breast cancer who don't respond well to initial dual HER2-targeted therapy plus chemotherapy.

  Recruiting Phase 2 Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou · NCT07340398

• Trastuzumab deruxtecan versus standard treatment for ovarian cancer that returned after PARP inhibitor therapy

  This study will test whether trastuzumab deruxtecan helps people with HER2-expressing recurrent ovarian, fallopian tube, or peritoneal cancer that progressed on prior PARP inhibitor therapy compared with standard chemotherapy or bevacizumab.

  Recruiting Phase 2 Yonsei University · Seoul, Seoul · NCT07340164

• Using blood ctDNA to compare two pre-surgery HER2-positive breast cancer regimens

  We will test whether two different pre-surgery drug combinations clear tumor DNA from the blood better in people with HER2-positive early breast cancer.

  Recruiting Phase 2 Shanghai Jiao Tong University School of Medicine · Shanghai · NCT07335081

• Fruquintinib with trastuzumab and XELOX for first-line treatment of HER2‑positive advanced stomach or GEJ cancer

  This trial will try fruquintinib together with trastuzumab and XELOX to see if it helps people with HER2‑positive advanced stomach or gastroesophageal junction cancer as their first treatment.

  Recruiting Phase 1/2 Henan Cancer Hospital · Zhengzhou, Henan · NCT07334431

• Disitamab vedotin plus trastuzumab and tislelizumab versus chemotherapy plus trastuzumab (± pembrolizumab) for HER2‑high advanced gastric or gastroesophageal junction adenocarcinoma

  This trial tests whether combining disitamab vedotin with trastuzumab and the immunotherapy tislelizumab works better than standard chemotherapy with trastuzumab (with or without pembrolizumab) as first‑line treatment for people with HER2‑high advanced gastric or gastroesophageal junction cancer.

  Recruiting Phase 3 RemeGen Co., Ltd. · Beijing, BJ-Beijing · NCT07315750

• Trastuzumab rezetecan for HER2-positive advanced solid tumors resistant to standard treatments

  This treatment gives trastuzumab rezetecan every three weeks to see if it helps adults with HER2-positive advanced solid tumors — including extramammary Paget's disease, rare tumors like urachal cancer, and urothelial carcinoma — that have stopped responding to standard treatments.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT07309770

• Trastuzumab deruxtecan for Russian patients with HER2-positive unresectable or metastatic breast cancer

  This study will see how well trastuzumab deruxtecan (T-DXd) works in Russian adults with unresectable or metastatic HER2-positive breast cancer who received at least one cycle.

  Recruiting Blokhin's Russian Cancer Research Center · Moscow · NCT07281001

• Intrathecal thiotepa plus trastuzumab for HER2‑positive breast cancer with leptomeningeal metastasis

  Testing whether injecting thiotepa together with trastuzumab into the cerebrospinal fluid through an Ommaya reservoir helps people with HER2‑positive breast cancer that has spread to the leptomeninges.

  Recruiting Phase 2 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT07263425

• Trastuzumab Rezetecan with or without Adebrelimab for HER2-expressing advanced urothelial cancer

  This study will test whether Trastuzumab Rezetecan alone or combined with the immunotherapy Adebrelimab helps people with HER2-expressing locally advanced or metastatic urothelial cancer.

  Recruiting at 3 sites Phase 2 Sun Yat-sen University · Guangzhou, Guangdong and 5 other locations · NCT07241793

• Nebivolol to protect the heart during trastuzumab treatment for HER2‑positive breast cancer

  This study will test whether taking nebivolol 5 mg can prevent drops in heart function in adults with newly diagnosed early or locally advanced HER2‑positive breast cancer who are starting trastuzumab.

  Recruiting Phase 2 Ain Shams University · Cairo · NCT07233499

• Trastuzumab Rezetecan for HER2‑low metastatic breast cancer with visceral crisis

  This Phase 2 trial tests Trastuzumab Rezetecan given every three weeks to see if it is safe and tolerable for adults with HER2‑low unresectable or metastatic breast cancer who are in visceral crisis.

  Recruiting Phase 2 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing, Beijing Municipality · NCT07203729

• Elacestrant plus trastuzumab deruxtecan for HR-positive, HER2-low or HER2-ultralow metastatic breast cancer after CDK4/6 and endocrine therapy

  This trial tests whether combining elacestrant with trastuzumab deruxtecan helps people with HR-positive, HER2-low or HER2-ultralow metastatic breast cancer that progressed after CDK4/6 inhibitor and endocrine treatment.

  Recruiting Phase 1/2 Dana-Farber Cancer Institute · Boston, Massachusetts · NCT07198724

• Comparing blood levels of the free‑DXd payload from trastuzumab‑deruxtecan by BMI in people with advanced or metastatic breast cancer

  This study will test whether body mass index changes blood levels of the free‑DXd payload in adults with locally advanced or metastatic HER2‑low or HER2‑positive breast cancer who are receiving trastuzumab‑deruxtecan.

  Recruiting at 6 sites Phase 4 Institut Claudius Regaud · Angers and 9 other locations · NCT07195344

• Tucatinib plus trastuzumab for HER3-mutant, HER2-not amplified metastatic breast cancer

  This trial will test whether combining tucatinib and trastuzumab helps people with metastatic or unresectable breast cancer whose tumors are HER2-negative but carry activating ERBB3 (HER3) mutations.

  Recruiting Phase 2 Institut Curie · Bordeaux and 8 other locations · NCT07193394

• Trastuzumab deruxtecan for adults with advanced breast cancer

  This trial tests trastuzumab deruxtecan in adults with advanced breast cancer to see if it is safe and works well.

  Recruiting RenJi Hospital · Shanghai · NCT07180264

• Subcutaneous trastuzumab‑pertuzumab before surgery for Algerian women with locally advanced HER2‑positive breast cancer

  This research will test whether giving the combined subcutaneous medicine Phesgo before surgery helps Algerian women with non‑metastatic HER2‑positive breast cancer clear invasive tumor from the breast and nearby lymph nodes.

  Recruiting Blida 1 University · Blida · NCT07166185

• T-DXd with or without Neratinib for HER2-positive breast cancer with brain metastases

  This trial tests whether adding Neratinib to Trastuzumab Deruxtecan helps treat HER2-positive breast cancer that has spread to the brain.

  Recruiting Phase 2 Fudan University · Shanghai · NCT07152782

• Bevacizumab added or not to T-DXd for HER2-low breast cancer with brain metastases

  This trial tests whether adding bevacizumab to trastuzumab deruxtecan helps people with HER2-low breast cancer that has spread to the brain.

  Recruiting Phase 2 Fudan University · Shanghai · NCT07150208

• Safety of combining pidnarulex (CX-5461) with trastuzumab deruxtecan for HER2-positive, HER2-low/ultralow breast and other HER2-expressing solid tumors

  This trial tests whether adding pidnarulex to trastuzumab deruxtecan is safe and finds the best dose for adults with HER2-positive, HER2-low/ultralow, or other HER2-expressing advanced or metastatic breast and solid tumors.

  Recruiting at 2 sites Phase 1 National Cancer Institute (NCI) · Boston, Massachusetts and 1 other locations · NCT07137416

• Trastuzumab and pertuzumab biosimilars with XELOX before surgery for HER2-positive rectal cancer

  This tests whether adding trastuzumab and pertuzumab biosimilars to XELOX chemotherapy before surgery can increase the complete tumor response in adults with locally advanced HER2-positive rectal cancer.

  Recruiting Phase 2 Peking Union Medical College Hospital · Beijing · NCT07108127

• Trastuzumab rezetecan with or without radiotherapy for HER2‑positive advanced breast cancer that has spread to the brain.

  This trial will test whether adding radiotherapy to trastuzumab rezetecan helps adults with HER2‑positive advanced breast cancer and untreated brain metastases control their brain tumors better than the drug alone.

  Recruiting Phase 2 Henan Cancer Hospital · Zhengzhou, Henan · NCT07100600

• Neoadjuvant oral paclitaxel with subcutaneous pertuzumab and trastuzumab for HER2-positive breast cancer

  This trial tests whether taking oral paclitaxel together with subcutaneous pertuzumab and trastuzumab before surgery helps people with HER2-positive breast cancer achieve a complete tumor response on pathology.

  Recruiting Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Beijing, Beijing Municipality and 8 other locations · NCT07095023

• Treatment options after targeted therapy stops working in advanced breast cancer

  This study will see how well different treatments work for people with advanced breast cancer who have stopped responding to CDK4/6 inhibitors, PIK3CA inhibitors, or T-DXd.

  Recruiting Hunan Cancer Hospital · Changsha, Hunan · NCT07073755

• RC48 with bevacizumab or pyrotinib for HER2-positive metastatic breast cancer after T-Dxd failure

  This trial will try RC48 together with either bevacizumab or pyrotinib in adults with HER2-positive metastatic breast cancer whose disease has progressed after trastuzumab deruxtecan (T-Dxd).

  Recruiting Phase 2 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT07065435

• Trastuzumab plus chemotherapy versus chemotherapy alone for first-line HER2-positive advanced biliary tract cancer

  This trial will test if adding trastuzumab to standard first-line chemotherapy helps people with HER2-positive advanced or metastatic biliary tract cancer control their disease longer than chemotherapy alone.

  Recruiting at 3 sites Phase 3 Tata Memorial Centre · Muzaffarpur, Bihar and 5 other locations · NCT07062263

• Toxicity markers for Trastuzumab‑Deruxtecan in advanced breast cancer

  This project will test whether blood markers can predict serious side effects, including interstitial lung disease, in adults with metastatic HER2‑positive or HER2‑low breast cancer who are treated with Trastuzumab‑Deruxtecan.

  Recruiting European Institute of Oncology · Milan · NCT07049133

• TQB2930 plus chemotherapy for HER2-positive advanced breast cancer

  This study tests whether TQB2930 with chemotherapy works better than trastuzumab with chemotherapy for people with HER2-positive advanced breast cancer who have already had at least two anti-HER2 treatments.

  Recruiting Phase 3 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Bengbu, Anhui and 74 other locations · NCT07047365

• Trastuzumab rezetecan followed by CDK4/6 inhibitor plus hormone therapy for HR+/HER2‑low/ultra‑low advanced breast cancer

  This trial will test whether starting with trastuzumab rezetecan and then switching to a CDK4/6 inhibitor plus endocrine therapy helps women with HR-positive, HER2-low or ultra-low advanced breast cancer live longer without disease progression.

  Recruiting Phase 2 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou, Guangdong · NCT07037199

• Trastuzumab deruxtecan versus standard chemotherapy for HER2-expressing (IHC 3+/2+) endometrial cancer

  This trial tests trastuzumab deruxtecan versus standard chemotherapy after surgery for adults with newly diagnosed HER2-expressing (IHC 3+/2+) endometrial cancer.

  Recruiting at 86 sites Phase 3 Daiichi Sankyo · Fort Lauderdale, Florida and 85 other locations · NCT07022483

• Combining sotorasib and trastuzumab deruxtecan for advanced KRAS G12C non-small cell lung cancer

  This trial tests whether giving sotorasib with trastuzumab deruxtecan is safe and can shrink tumors or slow progression in people with locally advanced or metastatic non-small cell lung cancer that has a KRAS G12C mutation and progressed after prior targeted therapy, immunotherapy, and chemotherapy.

  Recruiting at 9 sites Phase 1/2 National Cancer Institute (NCI) · Sacramento, California and 8 other locations · NCT07012031

• TQB2102 injection versus trastuzumab emtansine for HER2-positive advanced breast cancer

  This trial tests whether TQB2102 injection works as well as trastuzumab emtansine for adults with HER2-positive unresectable or metastatic breast cancer.

  Recruiting at 2 sites Phase 3 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Bengbu, Anhui and 30 other locations · NCT07008976

• Evorpacept plus trastuzumab and chemotherapy for metastatic HER2‑positive breast cancer after trastuzumab‑deruxtecan

  This trial will test whether adding evorpacept to trastuzumab and chemotherapy helps people with metastatic HER2‑positive breast cancer whose disease progressed after trastuzumab‑deruxtecan.

  Recruiting at 60 sites Phase 2 ALX Oncology Inc. · Phoenix, Arizona and 60 other locations · NCT07007559

• TQB2102 versus docetaxel with trastuzumab and pertuzumab for HER2-positive recurrent or metastatic breast cancer

  This trial will test whether TQB2102 works as well as docetaxel plus trastuzumab and pertuzumab for adults with HER2-positive recurrent or metastatic breast cancer.

  Recruiting Phase 3 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Hefei, Anhui and 24 other locations · NCT07003074

• Oral capecitabine plus trastuzumab versus paclitaxel plus trastuzumab for small HER2‑positive, node‑negative breast cancers as adjuvant treatment.

  This trial tests whether giving oral capecitabine with trastuzumab instead of paclitaxel with trastuzumab can prevent recurrence in women with small (≤2 cm), HER2‑positive, node‑negative breast cancer.

  Recruiting Phase 3 Fudan University · Shanghai, Shanghai Municipality · NCT06992882

• New treatment options for advanced endometrial cancer

  This study is testing a new combination of treatments for advanced endometrial cancer to see if it can help patients live longer without their cancer getting worse compared to standard chemotherapy.

  Recruiting at 205 sites Phase 3 AstraZeneca · Tucson, Arizona and 256 other locations · NCT06989112

• Vaccine targeting HER2 in locally advanced breast cancer

  This trial will test a vaccine that boosts the immune system to attack HER2-positive breast cancer in adults with locally advanced or high-risk disease.

  Recruiting Phase 1 Indiana University · Indianapolis, Indiana · NCT06949410

• Using Trastuzumab Emtansine after Trastuzumab Deruxtecan for HER2-Positive Breast Cancer

  This study is testing if giving trastuzumab emtansine right after trastuzumab deruxtecan helps people with advanced HER2-positive breast cancer who haven't responded to the first treatment.

  Recruiting Seoul National University Hospital · Seoul · NCT06928818

• Trastuzumab deruxtecan plus pembrolizumab versus platinum chemotherapy plus pembrolizumab for first-line HER2‑overexpressing non‑squamous NSCLC

  This trial will test whether combining trastuzumab deruxtecan with pembrolizumab works better than standard platinum‑based chemotherapy plus pembrolizumab as first treatment for adults with HER2‑overexpressing, PD‑L1 low (<50%) advanced non‑squamous NSCLC.

  Recruiting at 246 sites Phase 3 Daiichi Sankyo · Anchorage, Alaska and 245 other locations · NCT06899126

• 6 months versus 12 months of HER2-targeted therapy after a complete response to preoperative chemo for early HER2+ breast cancer

  This tests whether 6 months of HER2-targeted therapy works as well as 12 months for people with early HER2+ breast cancer who had a pathologic complete response after preoperative chemotherapy with trastuzumab.

  Recruiting at 604 sites Phase 3 Alliance for Clinical Trials in Oncology · Phoenix, Arizona and 701 other locations · NCT06876714

• Evaluating the effectiveness and safety of Trastuzumab Deruxtecan in advanced HER2-positive gastric cancer in China

  This study is testing how well Trastuzumab Deruxtecan works and how safe it is for people in China with advanced HER2-positive stomach cancer who are already receiving this treatment.

  Recruiting at 34 sites Daiichi Sankyo · Beijing and 39 other locations · NCT06846996

• Comparing JSKN003 and T-DM1 for advanced HER2-positive breast cancer

  This study is testing whether a new treatment called JSKN003 can work better than the standard drug T-DM1 for people with advanced HER2-positive breast cancer who have already received other treatments.

  Recruiting Phase 3 Shanghai JMT-Bio Inc. · Shanghai · NCT06846437

• Comparing Trastuzumab Deruxtecan and Endocrine Therapy for Low-HER2 Advanced Breast Cancer

  This study is testing whether a new drug called trastuzumab deruxtecan can help people with low HER2 advanced breast cancer feel better compared to standard hormone treatments they’ve already tried.

  Recruiting Phase 2 Yonsei University · Seoul · NCT06837792

• HLX22 plus trastuzumab deruxtecan for HER2-low, hormone receptor–positive advanced breast cancer

  This will test whether adding HLX22 to trastuzumab deruxtecan helps people with HER2-low, hormone receptor–positive advanced breast cancer who have progressed on or could not tolerate standard treatments.

  Recruiting Phase 2 Shanghai Henlius Biotech · Shanghai, Shanghai Municipality · NCT06832202

• Effectiveness and safety of T-DXd in Chinese patients with HER2 mutation-positive lung cancer

  This study is testing how well and safely a drug called T-DXd works for Chinese patients with advanced lung cancer that has HER2 mutations.

  Recruiting at 29 sites Daiichi Sankyo · Beijing and 35 other locations · NCT06809764

• Evaluating Pyrotinib for HER2-positive Advanced Breast Cancer

  This study is testing if a new drug called Pyrotinib, given with standard chemotherapy, can help people with advanced HER2-positive breast cancer feel better and improve their treatment outcomes.

  Recruiting Phase 1 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT06770296

• Collecting real-world data on trastuzumab-deruxtecan for advanced gastric cancer

  This study is collecting real-world information from patients with advanced gastric cancer who are being treated with trastuzumab-deruxtecan to see how well the treatment works and how it affects their lives.

  Recruiting Yonsei University · Seoul, Seoul · NCT06767436

• New treatment for HER2-positive gastric cancer using rilvegostomig and chemotherapy

  This study is testing a new treatment combining rilvegostomig with chemotherapy for people with HER2-positive gastric cancer to see if it works better than current standard treatments.

  Recruiting at 253 sites Phase 3 AstraZeneca · Anchorage, Alaska and 303 other locations · NCT06764875

• Using pyrotinib and trastuzumab for maintenance therapy in HER2-positive breast cancer

  This study is testing if using the drugs pyrotinib and trastuzumab together can help people with advanced HER2-positive breast cancer stay healthier and prevent brain tumors after their initial treatment.

  Recruiting Fujian Medical University Union Hospital · Fuzhou, Fujian · NCT06754059

• Testing a new drug for patients with metastatic HER2-negative breast cancer

  This study is testing a new drug called T-DXd to see if it can help adults with metastatic HER2-negative breast cancer feel better and improve their treatment outcomes.

  Recruiting at 3 sites Phase 2 Yale University · New Haven, Connecticut and 2 other locations · NCT06750484

• Imaging HER2-low breast cancers using a specialized PET scan

  This study is testing a new type of PET scan that uses a special version of a breast cancer drug to see if it can better find HER2-low breast cancers that might have been missed before.

  Recruiting Phase 1/2 Centre de recherche du Centre hospitalier universitaire de Sherbrooke · Sherbrooke, Quebec · NCT06732336

• Combination treatment for advanced HER2-positive gastric cancer

  This study is testing a new combination treatment for adults with advanced HER2-positive gastric cancer to see if it works better than the standard treatment.

  Recruiting at 219 sites Phase 3 Daiichi Sankyo · New Haven, Connecticut and 249 other locations · NCT06731478

• Combination treatment for advanced HER2-positive gastric cancer

  This study is testing a new combination of treatments for people with advanced HER2-positive gastric cancer to see if it works better than the standard chemotherapy options.

  Recruiting at 16 sites Phase 2 Qilu Hospital of Shandong University · Zhengzhou, Henan and 19 other locations · NCT06730373

• Observational study of trastuzumab deruxtecan for patients with HER2-low breast cancer

  This study is looking at how well trastuzumab deruxtecan works for people with HER2-low breast cancer that can't be removed by surgery or has spread, focusing on real-world experiences in Bulgaria and Slovenia.

  Recruiting at 3 sites AstraZeneca · Panagyurishte, Pazardzhik and 13 other locations · NCT06727227

• Neoadjuvant therapy for low-risk HER2-positive breast cancer patients

  This study is testing a new treatment plan for people with low-risk HER2-positive breast cancer to see if combining certain chemotherapy drugs with targeted therapy can work just as well with less intense treatment.

  Recruiting Peking University People's Hospital · Beijing, Beijing Municipality · NCT06722599

• Detecting Tumor DNA in Blood to Find T-DXd Candidates in HR+/HER2-Low Metastatic Breast Cancer

  We test whether persistent tumor DNA in blood after starting standard therapy can identify HR+ HER2-low metastatic breast cancer patients who may benefit from trastuzumab deruxtecan.

  Recruiting at 12 sites Phase 2 Unicancer · Amiens and 39 other locations · NCT06680596

• Genomic and transcriptomic markers predicting response to sacituzumab govitecan after trastuzumab deruxtecan in ER+/HER2-low metastatic breast cancer

  This trial will test whether DNA and RNA features from a fresh tumor biopsy can predict who responds to sacituzumab govitecan in people with ER-positive, HER2-low metastatic breast cancer who progressed after trastuzumab deruxtecan.

  Recruiting Phase 2 British Columbia Cancer Agency · Vancouver, British Columbia · NCT06665178

• Comparing Trastuzumab-Deruxtecan to standard therapy for early breast cancer patients with molecular relapse

  This study is testing if a new treatment called Trastuzumab-Deruxtecan can help early breast cancer patients with a relapse feel better compared to standard therapy options.

  Recruiting Phase 3 University of Ulm · Ulm · NCT06643585

• TL938 plus trastuzumab for HER2-positive metastatic colorectal cancer

  This Phase 2 test checks whether combining oral TL938 with trastuzumab helps adults with HER2-positive, RAS wild-type metastatic or unresectable colorectal cancer that has progressed after standard chemotherapy.

  Recruiting Phase 2 Suzhou Teligene Ltd. · Beijing, Beijing Municipality · NCT06589830

• Combination therapy of Disitamab Vedotin and Trastuzumab for HER2 positive gastric cancer

  This study is testing a new combination of two drugs, Disitamab Vedotin and Trastuzumab, to see if it can help people with advanced HER2 positive gastric cancer who haven't responded to other treatments.

  Recruiting Phase 1/2 Zhejiang Cancer Hospital · Hangzhou, Zhejiang · NCT06572319

• Evaluating trastuzumab deruxtecan in metastatic breast cancer with varying HER2 levels

  This study is testing how different levels of HER2 in metastatic breast cancer affect how well the drug trastuzumab deruxtecan works for patients.

  Recruiting at 26 sites Sun Yat-sen University · New Haven, Connecticut and 25 other locations · NCT06551220

• Treatment for HER2-negative metastatic breast cancer using two investigational drugs

  This study is testing if using two new drugs one after the other can help people with HER2-negative metastatic breast cancer live longer and feel better.

  Recruiting at 10 sites Phase 2 Dana-Farber Cancer Institute · Birmingham, Alabama and 10 other locations · NCT06533826

• Treatment for HER2-positive gastric and gastroesophageal junction cancer

  This study is testing a new treatment combining HLX22, trastuzumab, and chemotherapy to see if it helps people with advanced HER2-positive stomach cancer feel better compared to standard treatment.

  Recruiting at 206 sites Phase 3 Shanghai Henlius Biotech · Anaheim, California and 207 other locations · NCT06532006

• Trastuzumab deruxtecan versus CDK4/6 inhibitor plus hormone therapy as first-line treatment for HR-positive, HER2-low non-luminal advanced breast cancer.

  This trial will see if trastuzumab deruxtecan (T-DXd) works better than a CDK4/6 inhibitor plus endocrine (hormone) therapy as first-line treatment for adults with HR-positive, HER2-low advanced breast cancer that is classified as non-luminal by gene profiling.

  Recruiting at 79 sites Phase 2 MedSIR · Graz and 78 other locations · NCT06486883

• Comparing zanidatamab and trastuzumab for metastatic HER2-positive breast cancer treatment

  This study is testing whether a new treatment called zanidatamab, used with chemotherapy, works better than the standard treatment trastuzumab with chemotherapy for people with advanced HER2-positive breast cancer who haven't responded well to previous therapies.

  Recruiting at 163 sites Phase 3 Jazz Pharmaceuticals · Phoenix, Arizona and 165 other locations · NCT06435429

• Combining two anticancer drugs for treating advanced gastric and gastroesophageal junction cancers

  This study is testing a new combination of two cancer drugs to see if they can help people with advanced HER2-positive gastric or gastroesophageal junction cancers feel better and live longer.

  Recruiting Phase 1 National Cancer Institute (NCI) · Houston, Texas · NCT06364410

• Monitoring heart health in breast cancer patients receiving trastuzumab

  This study is testing if measuring a specific blood marker can help track heart health in breast cancer patients getting trastuzumab treatment, to see if it can replace traditional heart scans.

  Recruiting Vastra Gotaland Region · Gothenburg · NCT06340516

• Combining Anlotinib and Trastuzumab Deruxtecan for Advanced HER2-Low Breast Cancer

  This study is testing if combining two drugs, anlotinib and trastuzumab deruxtecan, can help people with advanced HER2-low breast cancer who have already had one round of chemotherapy.

  Recruiting Phase 1 Fudan University · Shanghai, Shanghai Municipality · NCT06331169

• Understanding how trastuzumab deruxtecan works in HER2 positive breast cancer

  This study is trying to understand why some people with HER2 positive breast cancer don’t respond to the treatment trastuzumab deruxtecan, to help improve future treatment options.

  Recruiting Samsung Medical Center · Seoul · NCT06330012

• Treatment of advanced breast cancer with Hemay022 and AI

  This study is testing if a new treatment called Hemay022, combined with hormone therapy, can help people with advanced breast cancer live longer without their cancer getting worse compared to a standard treatment.

  Recruiting Phase 3 Ganzhou Hemay Pharmaceutical Co., Ltd · Beijing · NCT06313983

• Comparing DP303c and trastuzumab emtansine for advanced HER2-positive breast cancer

  This study is testing a new injection called DP303c to see if it works better than trastuzumab emtansine for people with advanced HER2-positive breast cancer.

  Recruiting Phase 3 CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · Shanghai, Shanghai Municipality · NCT06313086

• Combining Darsilide with Trastuzumab and Patuzumab for Breast Cancer Treatment

  This study is testing if a new treatment combining Darsilide with two other drugs can help women with early or locally advanced HER2-positive breast cancer before they have surgery.

  Recruiting Phase 2 Henan Cancer Hospital · Henan, Henan · NCT06276868

• Treatment for HER2-positive gastric cancer after surgery

  This study is testing if a new combination treatment can help people with HER2-positive gastric cancer feel better after their surgery if they still have some cancer left.

  Recruiting Phase 2 Gruppo Oncologico del Nord-Ovest · Milan · NCT06253650

• Investigating the impact of HER2 receptor signaling on brown fat activity in breast cancer patients

  This study is testing how the HER2 receptor affects brown fat activity in breast cancer patients to see if it plays a role in weight management after treatment.

  Recruiting Copenhagen University Hospital, Rigshospitalet · Copenhagen · NCT06222957

• Using Shengmai San to Prevent Heart Issues from Breast Cancer Treatment

  This study is testing whether a traditional Chinese medicine called Shengmai San can help prevent heart problems in people with HER2 positive breast cancer who are receiving certain chemotherapy treatments.

  Recruiting Phase 3 Zhejiang Cancer Hospital · Hangzhou, Zhejiang · NCT06214195

• Neoadjuvant treatment for HER2-positive breast cancer without chemotherapy

  This study is testing a new treatment using tucatinib, trastuzumab, and pertuzumab for people with stage II-III HER2-positive breast cancer to see if they can be treated without chemotherapy.

  Recruiting Phase 1 The Netherlands Cancer Institute · Amsterdam · NCT06162559

• Combining pembrolizumab, trastuzumab, and chemotherapy for HER2+ esophagogastric cancer

  This study is testing if adding pembrolizumab and trastuzumab to standard chemotherapy can help people with resectable HER2+ esophagogastric cancer do better in their treatment.

  Recruiting at 9 sites Phase 2 Memorial Sloan Kettering Cancer Center · Boston, Massachusetts and 9 other locations · NCT06123338

• Combination of Trastuzumab Deruxtecan and Afatinib for HER2-low Advanced Gastric Cancer

  This study is testing a new combination of two drugs, Trastuzumab Deruxtecan and Afatinib, to see if it can help people with HER2-low advanced gastric cancer who don’t have many treatment choices.

  Recruiting Phase 1/2 Samsung Medical Center · Seoul · NCT06085755

• Using Trastuzumab Deruxtecan to treat brain cancer

  This study is testing if a new drug called trastuzumab deruxtecan can effectively treat brain cancer in adults with specific types of tumors that have the HER2 protein.

  Recruiting Phase 2 Memorial Sloan Kettering Cancer Center · New York, New York · NCT06058988

• Combination therapy for HER2-positive breast cancer

  This study is testing a new combination of treatments for women with HER2-positive breast cancer to see if it helps them respond better to therapy before surgery.

  Recruiting First Affiliated Hospital of Fujian Medical University · Fuzhou, Fujian · NCT06035679

• Tucatinib combined with radiation for HER2-positive breast cancer with leptomeningeal disease

  This study is testing if combining radiation with a new treatment for HER2-positive breast cancer can help patients with brain involvement live longer and feel better.

  Recruiting at 2 sites Phase 2 Sunnybrook Health Sciences Centre · Ottawa, Ontario and 1 other locations · NCT06016387

• Neoadjuvant treatment for ER+/HER2+ breast cancer using a combination of drugs

  This study is testing a new combination of drugs to see if it helps women with early or locally advanced HER2-positive breast cancer shrink their tumors before surgery.

  Recruiting at 2 sites Phase 2 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Hubei and 1 other locations · NCT06000917

• Treatment for HER2-positive breast cancer with limited metastases

  This study tests if a new treatment can help people with HER2-positive breast cancer that has spread to a few other places in the body and aims to improve their chances of recovery.

  Recruiting Phase 2 The Netherlands Cancer Institute · Amsterdam · NCT05982678

• Using targeted therapy for HER2 positive gastrooesophageal cancer after surgery

  This study is testing if a new targeted therapy called trastuzumab deruxtecan can help patients with HER2 positive gastrooesophageal cancer who still have traces of cancer after surgery and chemotherapy.

  Recruiting at 12 sites Phase 2 University of Southampton · Guildford, Surrey and 13 other locations · NCT05965479

• Combination treatment for metastatic HER2-positive breast cancer

  This study is testing a new combination of medications for people with HER2-positive metastatic breast cancer who haven't responded to previous treatments, to see if it can help them feel better and manage their disease.

  Recruiting at 9 sites Phase 2 Institut Curie · Clermont-Ferrand, Clermont Ferrand and 12 other locations · NCT05955170

• Evaluating trastuzumab deruxtecan for patients with low HER2 metastatic breast cancer

  This study is testing a new drug called trastuzumab deruxtecan to see if it can help people with low HER2 metastatic breast cancer live longer before needing a different treatment.

  Recruiting at 68 sites Phase 3 Daiichi Sankyo · Miami Beach, Florida and 87 other locations · NCT05950945

• Observational study on HER2-low breast cancer treatment with Trastuzumab Deruxtecan

  This study is testing how well Trastuzumab deruxtecan works for adults with advanced HER2-low breast cancer who have already had chemotherapy.

  Recruiting at 26 sites Daiichi Sankyo · Graz and 215 other locations · NCT05945732

• Comparing trastuzumab deruxtecan to standard treatment for HER2-positive breast cancer

  This study is testing if a new drug called trastuzumab deruxtecan can work better than standard treatment for people with early-stage HER2-positive breast cancer before surgery.

  Recruiting Phase 2 Karolinska University Hospital · Malmö and 6 other locations · NCT05900206

• Short-course treatment for early HER2-positive breast cancer

  This study is testing a shorter treatment plan with two medications for early HER2-positive breast cancer to see if it works just as well as the usual year-long treatment but with fewer side effects.

  Recruiting Phase 2 Shanghai Jiao Tong University School of Medicine · Shanghai, Shanghai Municipality · NCT05891561

• New treatment for HER2-positive recurrent or metastatic breast cancer

  This study is testing a new combination treatment for people with HER2-positive recurrent or metastatic breast cancer to see if it works better than the standard treatment.

  Recruiting Phase 3 Shanghai JMT-Bio Inc. · Beijing, chaoyang · NCT05838066

• Evaluating GI-102 for advanced solid tumors with or without other cancer drugs

  This study is testing a new cancer treatment called GI-102, both on its own and with other cancer drugs, to see how safe it is and how well it works for people with advanced solid tumors.

  Recruiting at 11 sites Phase 1/2 GI Innovation, Inc. · Scottsdale, Arizona and 10 other locations · NCT05824975

• Treatment for breast cancer patients with leptomeningeal disease

  This study is testing a new treatment combining tucatinib, capecitabine, and intrathecal trastuzumab to see if it can help people with HER2-positive metastatic breast cancer and leptomeningeal disease live longer.

  Recruiting at 10 sites Phase 2 Unicancer · Bordeaux and 10 other locations · NCT05800275

• Testing a new drug combination for HER2-positive inflammatory breast cancer

  This study is testing a new combination of two drugs to see if they can safely and effectively treat people with stage III HER2-positive inflammatory breast cancer who haven't had treatment before.

  Recruiting at 3 sites Phase 2 Dana-Farber Cancer Institute · Boston, Massachusetts and 2 other locations · NCT05795101

• Combination of trastuzumab and pertuzumab for treating cancers with HER2 mutations

  This study is testing if a combination of two cancer drugs, trastuzumab and pertuzumab, can help adults and young people with cancers that have HER2 mutations or amplifications.

  Recruiting at 24 sites Phase 2/3 Cancer Research UK · Belfast and 26 other locations · NCT05786716

• Treatment for hormone receptor positive HER2 positive breast cancer after neoadjuvant therapy

  This study is testing if combining two drugs, trastuzumab and nelatinib, can help people with hormone receptor positive HER2 positive breast cancer who still have cancer after initial treatment feel better compared to the usual combination of trastuzumab and pertuzumab.

  Recruiting Phase 3 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou · NCT05760612

• Combination therapy for advanced HER2-positive biliary tract cancer

  This study is testing a new combination treatment for people with advanced HER2-positive biliary tract cancer to see if it can help them live longer and feel better.

  Recruiting Phase 1/2 Yonsei University · Seoul · NCT05749900

• Neoadjuvant therapy for HER2-positive early breast cancer

  This study is testing if a new drug called trastuzumab-deruxtecan can work better than standard chemotherapy for people with early HER2-positive breast cancer to see if it helps them respond better to treatment.

  Recruiting at 40 sites Phase 2 Women's Cancer Study Group GmbH · Baden-Baden, Baden-Wurttemberg and 43 other locations · NCT05704829

• Combination treatment for HER2-positive metastatic solid tumors with brain metastases

  This study is testing if a combination of two drugs can help people with HER2-positive metastatic solid tumors that have spread to the brain feel better and live longer.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT05673928

• Combining Tucatinib and Trastuzumab for HER2 Positive Rectal Cancer

  This study is testing if combining two cancer drugs, tucatinib and trastuzumab, with standard chemotherapy can help people with HER2 positive rectal cancer have better treatment results.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT05672524

• Combination therapy for advanced HER2-positive gastric cancer

  This study is testing a new combination of three drugs to see if it can help people with advanced HER2-positive gastric cancer who didn’t get better with their first treatment.

  Recruiting Phase 1/2 Kangbuk Samsung Hospital · Seoul · NCT05640830

• Combination treatment for HR+/HER2+ breast cancer

  This study is testing a new combination treatment for patients with stage II-III HR+/HER2+ breast cancer to see if it works better than the standard treatment before surgery.

  Recruiting Phase 2 Shengjing Hospital · Shenyang, Liaoning · NCT05638594

• Observing patient outcomes in breast cancer patients treated with trastuzumab deruxtecan

  This study is looking to see how well trastuzumab deruxtecan works for people with certain types of advanced breast cancer and how they feel about their treatment.

  Recruiting at 105 sites AstraZeneca · Amberg and 108 other locations · NCT05573893

• Combining Eribulin and a Trastuzumab-biosimilar for Advanced HER2-positive Breast Cancer

  This study is testing if combining two cancer drugs, eribulin and a trastuzumab-biosimilar, can help people with advanced HER2-positive breast cancer who have already tried other treatments.

  Recruiting Phase 2 Seoul National University Hospital · Seoul · NCT05530057

• Comparing treatments for advanced HER2-positive salivary gland cancer

  This study is testing if a new drug called T-DM1 works better than the usual treatment for people with advanced HER2-positive salivary gland cancer, while also looking at another drug for those with lower levels of HER2.

  Recruiting at 143 sites Phase 2 NRG Oncology · Birmingham, Alabama and 153 other locations · NCT05408845

• Imaging HER2+ Breast Cancer with Brain Metastasis using a New Scan

  This study is testing a new type of scan to see if it can help doctors better understand how well a treatment works for people with HER2+ breast cancer that has spread to the brain.

  Recruiting Phase 4 City of Hope Medical Center · Duarte, California · NCT05376878

• Testing a combination of two anti-cancer drugs for HER2-positive solid tumors

  This study is testing a combination of two cancer drugs to see if they can safely help people with advanced HER2-positive solid tumors.

  Recruiting at 15 sites Phase 1 National Cancer Institute (NCI) · Duarte, California and 17 other locations · NCT05372614

• HER2-targeted vaccine combined with standard chemotherapy for breast cancer

  This study is testing if adding a new vaccine to standard chemotherapy can help people with HER2-positive breast cancer have better treatment results.

  Recruiting Phase 2 H. Lee Moffitt Cancer Center and Research Institute · Tampa, Florida · NCT05325632

• Neoadjuvant therapy with or without Inavolisib for early HER2-positive breast cancer

  This study is testing if adding a new drug called Inavolisib to standard treatment can help women with early HER2-positive breast cancer respond better before surgery.

  Recruiting at 53 sites Phase 2 GBG Forschungs GmbH · Essen, North Rhine-Westphalia and 61 other locations · NCT05306041

• Comparing targeted therapies for HER2 positive early breast cancer after surgery

  This study is testing whether a new combination of treatments can help women with HER2 positive early breast cancer do better after surgery compared to sticking with their original therapy.

  Recruiting Phase 2 Fujian Medical University Union Hospital · Fuzhou, Fujian · NCT05292742

• Combination treatment for HER2 positive metastatic colorectal cancer

  This study is testing a new combination of tucatinib, trastuzumab, and mFOLFOX6 to see if it helps people with HER2 positive metastatic colorectal cancer more than the usual treatments.

  Recruiting at 298 sites Phase 3 Seagen Inc. · Glendale, Arizona and 365 other locations · NCT05253651

• Evaluating GLSI-100 immunotherapy for HER2 positive breast cancer

  This study is testing a new immunotherapy called GLSI-100 to see if it can help prevent breast cancer from coming back in patients who are at high risk and have HER2 positive breast cancer.

  Recruiting at 154 sites Phase 3 Greenwich LifeSciences, Inc. · Mobile, Alabama and 178 other locations · NCT05232916

• Combination treatment for stage II-III triple-positive breast cancer

  This study is testing a new combination treatment for women with stage II-III triple-positive breast cancer to see if it helps shrink tumors before surgery.

  Recruiting Phase 2 Shengjing Hospital · Shenyang, Liaoning · NCT05228951

• Using trastuzumab and pertuzumab to improve survival in HER2+ esophageal cancer

  This study is testing if adding two targeted therapies, trastuzumab and pertuzumab, to standard treatment can help people with HER2-positive esophageal cancer live longer.

  Recruiting Phase 3 Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Amsterdam · NCT05188313

• CA-4948 combined with chemotherapy and immunotherapy for advanced gastric and esophageal cancer

  This study is testing a new treatment combining CA-4948 with chemotherapy and immunotherapy to see if it helps people with advanced stomach and esophageal cancer who haven't had other treatments yet.

  Recruiting Phase 1 Washington University School of Medicine · St Louis, Missouri · NCT05187182

• Comparing two treatment regimens for HER-2 positive breast cancer

  This study is testing two different treatment plans for people with HER-2 positive breast cancer to see which one works better before surgery.

  Recruiting Phase 3 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guandong, Guangdong · NCT05159193

• Treatment adjustment for HER2 positive breast cancer after initial therapy

  This study is testing if adjusting treatment for early HER2 positive breast cancer based on blood tests can help patients do better after their initial therapy.

  Recruiting Phase 2 AC Camargo Cancer Center · São Paulo · NCT04993014

• Combining Pyrotinib and ARX788 for treating HER2-positive breast cancer

  This study is testing a new combination of two drugs, pyrotinib and ARX788, to see if it can help women with stage II-III HER2-positive breast cancer who haven't responded well to other treatments.

  Recruiting Phase 2 Shengjing Hospital · Shenyang, Liaoning · NCT04983121

• Comparing two treatments for early-stage HER2-positive breast cancer after surgery

  This study is testing whether a new treatment combining T-DM1 and trastuzumab can help people with early-stage HER2-positive breast cancer feel better and live longer after surgery compared to a standard treatment.

  Recruiting at 46 sites Phase 2 Dana-Farber Cancer Institute · San Francisco, California and 52 other locations · NCT04893109

Showing recruiting studies first, then the newest. Describe your situation to find the ones that fit you.

Quick answers

How many clinical trials of Trastuzumab are recruiting right now?

161, as of November 12, 2026. 1 of them was first registered in the last 30 days. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 52 countries. The most sites are in China (85 trials), United States (44 trials), South Korea (22 trials), Italy (20 trials), France (19 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 73, Phase 3: 35, Phase 1/2: 11, Phase 1: 10. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →